Výsledky vyhledávání - "Yelena Janjigian"

Akademický článek

Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors

Autor: Stephanie King, David Faleck, Yelena Janjigian, Steven B Maron, Darren Cowzer, Patrick T Magahis, Mark Schattner, Monika Laszkowska

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)

Background Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint inhibitor (ICI) efficacy in lung cancer and melanoma, but thorough characterization

Externí odkaz: https://doaj.org/article/04baa71c765345c2895d824f70e4808e

Zobrazit plný text záznamu

Akademický článek

Management of immune-related cutaneous adverse events with dupilumab

Autor: Paul Chapman, Mario E Lacouture, Lukas kraehenbuehl, Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Elizabeth A Quigley, Alina Markova

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)

Immune checkpoint inhibitors (ICI) target the PD-1/PD-L1 and CTLA-4 pathways and allows the immune system to deliver antitumor effects. However, it is also associated with well-documented immune-related cutaneous adverse events (ircAEs), affecting up

Externí odkaz: https://doaj.org/article/6e5a3ab13eac4fd5b7c33c92be3e1a08

Zobrazit plný text záznamu

Akademický článek

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Publikováno v: Communications Biology, Vol 4, Iss 1, Pp 1-20 (2021)

Joshi, Gomes et al. employ a chemical modulation approach of the cellular interactome to a hyperconnectivity state and show association with the increased response of pancreatic cancer cell lines to specific drugs, including those that target the MAP

Externí odkaz: https://doaj.org/article/c73d69998238486ba39d6f85c901b64d

Zobrazit plný text záznamu

Akademický článek

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

Autor: Andres Lopez-Albaitero, Hong Xu, Hongfen Guo, Linlin Wang, Zhihao Wu, Hoa Tran, Sarat Chandarlapaty, Maurizio Scaltriti, Yelena Janjigian, Elisa de Stanchina, Nai-Kong V. Cheung

Publikováno v: OncoImmunology, Vol 6, Iss 3 (2017)

T-cell-based therapies have emerged as one of the most clinically effective ways to target solid and non-solid tumors. HER2 is responsible for the oncogenesis and treatment resistance of several human solid tumors. As a member of the HER family of ty

Externí odkaz: https://doaj.org/article/1e7fe89c0b5049b58a055d36296e5215

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání